These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38094891)

  • 1. Inhibitory effect of napabucasin on arbidol metabolism and its mechanism research.
    Nie J; Xia H; Liu YN; Yu Y; Xu RA
    Front Pharmacol; 2023; 14():1292354. PubMed ID: 38094891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of drug-drug interactions and CYP3A4 variants on alectinib metabolism.
    Liu YN; Chen J; Wang J; Li Q; Hu GX; Cai JP; Lin G; Xu RA
    Arch Toxicol; 2023 Aug; 97(8):2133-2142. PubMed ID: 37209178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism.
    Zhou Q; Ye F; Ye Z; Gao N; Kong Q; Hu X; Qian J; Wu B
    PeerJ; 2023; 11():e16601. PubMed ID: 38089912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the antitumor drugs adagrasib and asciminib on apixaban metabolism in vitro and in vivo.
    Shen Y; Chen X; Wu H; Xia H; Xu RA
    Chem Biol Interact; 2024 Aug; 399():111146. PubMed ID: 39002878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the inhibitory effect of isavuconazole on flumatinib metabolism
    Liu YN; Xu X; Nie J; Hu Y; Xu X; Xu RA; Du X
    Front Pharmacol; 2023; 14():1168852. PubMed ID: 37214442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impacts of CYP3A4 genetic polymorphism and drug interactions on the metabolism of lurasidone.
    Li Q; Wang J; Wang ZL; Shen Y; Zhou Q; Liu YN; Hu GX; Cai JP; Xu RA
    Biomed Pharmacother; 2023 Dec; 168():115833. PubMed ID: 37935069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Avitinib on CYP450 Enzyme Activity in vitro and in vivo in Rats.
    Shi Y; Meng D; Wang S; Geng P; Xu T; Zhou Q; Zhou Y; Li W; Chen X
    Drug Des Devel Ther; 2021; 15():3661-3673. PubMed ID: 34456561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of Resveratrol on the pharmacokinetic profile of tofacitinib and the underlying mechanism.
    Ye Z; Hu J; Wang J; Liu YN; Hu GX; Xu RA
    Chem Biol Interact; 2023 Apr; 374():110398. PubMed ID: 36773832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of myricetin and quercetin on ticagrelor metabolism and the underlying mechanism.
    Wang J; Hu Y; Li Q; Liu YN; Lin J; Xu RA
    Chem Biol Interact; 2024 Apr; 392():110924. PubMed ID: 38401715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory mechanism of vortioxetine on CYP450 enzymes in human and rat liver microsomes.
    Zhan Y; Wang A; Yu Y; Chen J; Xu X; Nie J; Lin J
    Front Pharmacol; 2023; 14():1199548. PubMed ID: 37790811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS.
    Lin QM; Pang NH; Li YH; Huang HL; Zhang XD; Hu GX; Wang ZS
    Chem Biol Interact; 2019 Sep; 310():108744. PubMed ID: 31299239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of shikonin on the metabolism of lapatinib in vitro, and in vivo.
    Hu Y; Xie S; Xia H; Chen J; Yang Y; Zhan R
    Toxicol Appl Pharmacol; 2024 Jan; 482():116797. PubMed ID: 38160892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessments of CYP‑inhibition‑based drug-drug interaction between vonoprazan and poziotinib
    Zhou S; Zhao FL; Wang SH; Wang YR; Hong Y; Zhou Q; Geng PW; Luo QF; Cai JP; Dai DP
    Pharm Biol; 2023 Dec; 61(1):356-361. PubMed ID: 36728978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitory effect of imperatorin on dabrafenib metabolism in vitro and in vivo.
    Xia H; Wu H; Chen J; Xu X; Tan W; Xu RA
    Chem Biol Interact; 2024 Aug; 399():111131. PubMed ID: 38964639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative metabolism of tussilagone in rat and human liver microsomes using ultra-high-performance liquid chromatography coupled with high-resolution LTQ-Orbitrap mass spectrometry.
    Zhang XS; Ren W; Bian BL; Zhao HY; Wang S
    Rapid Commun Mass Spectrom; 2015 Sep; 29(18):1641-50. PubMed ID: 26467116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bergapten on the pharmacokinetics of macitentan in rats both
    Xu J; Zhou Q; Hou P; Wang Y; Geng P; Lu Z; Zhou Y; Dai D; Wang S
    Front Pharmacol; 2023; 14():1204649. PubMed ID: 37492094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism.
    Gao N; Zhang X; Hu X; Kong Q; Cai J; Hu G; Qian J
    Front Pharmacol; 2022; 13():794931. PubMed ID: 35359868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of apatinib on the pharmacokinetics of tramadol and O-desmethyltramadol in rats.
    Bao SS; Tang PF; Gao NY; Xiao ZX; Qian JC; Zheng L; Hu GX; Xu HH
    PeerJ; 2023; 11():e16051. PubMed ID: 37719112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans.
    Deng P; Zhong D; Yu K; Zhang Y; Wang T; Chen X
    Antimicrob Agents Chemother; 2013 Apr; 57(4):1743-55. PubMed ID: 23357765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties and bioequivalence of two formulations of arbidol: an open-label, single-dose, randomized-sequence, two-period crossover study in healthy Chinese male volunteers.
    Liu MY; Wang S; Yao WF; Wu HZ; Meng SN; Wei MJ
    Clin Ther; 2009 Apr; 31(4):784-92. PubMed ID: 19446151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.